Business Wire

ZEDRA

14.9.2020 09:02:10 CEST | Business Wire | Press release

Share
ZEDRA Announces Milestone Acquisition of Global Expansion Specialist Fitzgerald & Law.

ZEDRA, the fast growing global specialist in Corporate, Fund and Active Wealth Solutions has announced the acquisition of Fitzgerald & Law (F&L), London’s leading firm of global expansion advisers. In addition to offering a wide range of specialised expansion advice to companies setting up in the UK, F&L provides a full suite of award-winning tax, HR and financial compliance services that supports those companies as they grow. At the same time as this transaction, ZEDRA will acquire the Global Expansion Advisory Network operating in over 70 countries, of which F&L is a founding firm. F&L’s continued membership of the GEA Network means that companies expanding into countries other than the UK can receive the same unparalleled support.

This acquisition marks a step change for ZEDRA’s corporate services offering and will substantially enlarge the Group’s reach to fast-growing US technology companies. F&L has a particular focus on helping US companies wishing to establish and grow a UK presence, and more broadly advises companies from all over the world on expanding their footprint in other territories globally. F&L has a strong track record in multi-territory HR consulting, international tax compliance, corporate compliance and accounting services.

The acquisition will bolster ZEDRA’s presence in the all-important London market with F&L’s London team of over 70 helping to double ZEDRA’s workforce in the UK. ZEDRA also welcomes a team of 14 in Romania who provide vital support to the outsourcing services function. The F&L San Francisco office will continue to play a key role in business development and supporting clients on the US West Coast.

Ivo Hemelraad, ZEDRA Chief Executive Officer, commented, “We are delighted to welcome the employees and clients of Fitzgerald & Law to ZEDRA and to extend our corporate services reach to the US West Coast where F&L has an enviable and growing reputation. Adding their knowledge and expertise to our Group will significantly extend the support we can offer to our international corporate clients and help them optimise their global expansion strategies.”

Gabriel Parrish, Senior Partner at F&L added, “Joining ZEDRA at this time with its global footprint of offices and international client base is a natural fit for F&L, and a logical step forward in our growth plans. Our clients will now have access to an additional range of services to support their business ambitions.”

Fitzgerald & Law will ultimately rebrand to ZEDRA.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EVE Energy Strengthens European Operations Through Compliance, Local Manufacturing, and Regional Services2.7.2026 08:30:00 CEST | Press release

The Smarter E Europe 2026 opened in Munich on June 23 and runs through June 25, gathering global players from the clean energy sector on one of Europe’s most influential trade exhibition platforms. EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, all-scenario storage solutions, and high-performance EV batteries — showcasing its lithium-sodium dual-technology platform, full product portfolio, and localized European operational layout. During the exhibition, European clients showed strong interest in the company’s product performance and placed strong emphasis on sustained adherence to the EU’s evolving regulatory standards. This industry attitude further underscores that regulatory compliance readiness has become a fundamental prerequisite for accessing the European clean energy market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701651416/en/ The BMW iX3 displayed at the EVE Energy booth

Braun Launches the Next Generation of Electric Shaver With Braun NEVO Introducing a New Dawn of Smooth Touch2.7.2026 08:00:00 CEST | Press release

With over 100 years of exceptional German craftsmanship, Braun introduces Braun NEVO, an electric shaver redefining what a close shave and smooth skin mean. Every element has been reimagined: the sleek unibody stainless steel handle, the revolutionary AeroTouch™ Technology and advanced personalized display deliver a perfectly close shave without sacrificing comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701842080/en/ Braun NEVO Shaver Oliver Grabes, Braun Head of Design, said: “At Braun, we set out to reimagine the shaving experience which led to the development of AeroTouch™ Shaving Technology, a cutting system engineered for ultra-low friction on the skin and high efficiency. This makes Braun NEVO our best shaver* setting a new standard for smooth skin.” Introducing the revolutionary world’s first AeroTouch™ Technology, featuring 250 diamond-sharp cutting edges and an exclusive Ultra gliding foil for a smooth g

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member2.7.2026 08:00:00 CEST | Press release

Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST, as a second independent director, following the earlier addition of Diala EZZEDDINE a seasoned US-based biotech executive and entrepreneur. Camilla SYLVEST is an experienced pharmaceutical executive and global business leader, having spent nearly three decades at Novo Nordisk A/S, where she most recently served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability. She currently serves on the Boards of Argenx SE, Getinge AB, and Zealand Pharma A/S, and has previously served on the Board of Danish Crown A/S and as

Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release

Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye